Diagnosis and treatment of C3 glomerulopathy of transplant kidney
WEN Ji-qiu
Abstract：C3 glomerulopathy is a newly proposed disease entity which is characterized by predominantly complement C3 deposition in the glomeruli.C3 glomerulopathy has 2 variants,including C3 glomerulonephritis and dense deposit disease.This disease carries a high risk of post-kidney transplant recurrence.The underlying pathophysiology is the acquired or inherited complement factor abnormalities or dysregulation of complement regtlating system,leading ultimately to persistent C3 activation and its deposition in the mesangium and glomerular basement membrane.Therefore,genetic testing plays an important role in management and is conducive to understanding the pathogenesis of C3 glomerulopathy.The clinical manifestations of C3 glomerulopathy are non-specific,including hematuria,proteinuria and serum creatinine elevation.Renal allograft biopsy frequently shows membranoproliferative glomerulanephritis-like pattern.Currently,there is no specific treatment for recurrent C3 glomerulopathy.Monoclonal antibody eculizumab has only been shown to be effective in a subset of patients.Therefore,the effect and side-effects of eculizumab should be verified in the future in large number of cases.
Keywords：C3 glomerulopathykidney transplantEculizumabgenetic testing
Publication Date：2017-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 794-797 )